Selpercatinib capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Retevmo / Retsevmo
- Company
- Eli Lilly and Company (US); Eli Lilly Nederland B.V. (EU authorization holder)
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- Selected EU indications: Monotherapy for adults with advanced RET fusion-positive non-small cell lung cancer without previous RET-inhibitor treatment. For adults and children aged at least 2 years, specified uses include advanced RET fusion-positive thyroid cancer refractory to radioactive iodine when appropriate, advanced RET-mutant medullary thyroid cancer, and advanced RET fusion-positive solid tumors with limited benefit from or exhaustion of non-RET treatment options. This summary does not establish the approved indications in China.
- Indication source and scope
- Web page accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
- China availability status
- Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo
- Retevmo / Retsevmo — EMA European public assessment report
Regulatory medicine overview · Web page accessed 2026-11-02
English primary regulatory source opened and reviewed. Selected EU indications and the EU authorization holder are reported; this is not evidence of Chinese approval.
- FDA traditional approval of selpercatinib for RET fusion-positive solid tumors
Regulatory approval announcement · 2026-07-14
Opened FDA source confirms the US brand Retevmo and Eli Lilly. The main summary above follows the separately linked EU scope.
Evidence reviewed:
Open the interactive record, public price references and discussions